LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients

(PRLEAP.COM) Denver, CO — LegalView recently reported on its mesothelioma information blog of a scientific discovery that may offer varied levels of relief to mesothelioma cancer patients. Several Australian scientists used a skin cancer cream treatment known as Imiquimod combined with an additional cancer treatment known as antiCD40 to treat mesothelioma tumor patients. Nearly 50 percent of the mice tested in the study showed positive results, although treatment side effects were found to be severe.

Mesothelioma is a rare form of cancer that is caused by the exposure and inhalation of asbestos fibers and dust. Unfortunately, many individuals are at risk for the development of the cancer even those who were not employed in occupations where asbestos was readily available at high exposure levels.

Individuals who suffer from mesothelioma cancer or believe they may have the beginnings of mesothelioma cancer should seek medical attention immediately. Additionally, receiving a free legal consultation from an experienced mesothelioma lawyer may assist in the development of any potential mesothelioma lawsuits that occur. Such litigation may be able to result in monetary compensation for a victim to pay for mesothelioma treatments. To learn more visit the LegalView mesothelioma information portal at http://mesothelioma.legalview.com/

LegalView also offers a multitude of additional information on more than 100 legal topics ranging from the latest information on traumatic brain injuries to recent controversial pharmaceutical topics such as the Ketek liver damage scare or the Baxter Heparin recall.

Traumatic brain injury (TBI) affects approximately 5.4 million Americans, with an increasing number of victims deriving from veterans returning from the war in Iraq. TBI can have a devastating impact on not only the victim, but also on family, friends and co-workers of a TBI patient. Additionally, when an individual avoids or denies treatment for their brain injury symptoms their condition will likely worsen and cause dramatic negative impact on their life as well as others around them.

Both Ketek and Heparin have repeatedly made headlines for their dangerous side effects that have been investigated by the U.S. Food and Drug Administration (FDA). Ketek is an antibiotic used to treat upper respiratory infections such as community acquired pneumonia or bronchitis. Individuals who have taken the prescription medication and feel they may be suffering from liver-related conditions should speak with a medical professional as well as consult a pharmaceutical attorney in case a potential Ketek class action lawsuit becomes necessary.

Baxter’s Heparin is a blood thinner that is administered to patients undergoing major surgery including heart damage or kidney failure. The drug has been used in the United States since the 1930s and is often imported from Chinese manufacturers. The company has since halted sale of the drug, but those who may be affected by the Baxter Heparin dangers should receive medical assistance as well as speak to a qualified pharmaceutical lawyer for additional assistance.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com’s superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.
Contact Information
Katie Kelley
LegalView.com
720-226-6613
Email LegalView.com

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy